Risk of Hair Loss with Semaglutide for Weight Loss
==================================================
* Mohit Sodhi
* Ramin Rezaeianzadeh
* Abbas Kezouh
* Connor Frey
* Mahyar Etminan
## ABSTRACT
GLP-1 (glucagon-like peptide-1) agonists including semaglutide are some of the most prescribed medications in the world. Many recent studies have quantified their adverse events with a focus on gastrointestinal adverse events. However, no large epidemiologic study has investigated the risk of hair loss with these medications. We conducted a retrospective cohort study using a large health claims database to investigate this risk. Using a random sample of 16 million patients, we identified new users of semaglutide and an active comparator bupropion-naltrexone. We excluded those with a diagnosis of diabetes or use of antihyperglycemics prior to cohort entry. Cohort members were followed from the first date of a study drug prescription to the diagnosis of hair loss. We adjusted for age, sex, geographic location, depression, steroid use, hypothyroidism, polycystic ovary syndrome, and anemia. Our cohort included 1,926 semaglutide users and 1,348 users of bupropion-naltrexone. The incidence of hair loss was higher among the semaglutide group than the active comparator, bupropion-naltrexone. The adjusted hazard ratio for hair loss for all patients using semaglutide, for men, and for women compared to bupropion-naltrexone were 1.52 (95% confidence interval (CI):0.86-2.69), 0.86 (95% CI: 0.05-14.49), and 2.08 (95% CI: 1.17-3.72) respectively. Our results demonstrate an increased risk of hair loss with semaglutide in women. Future studies are required to ascertain the association between semaglutide and hair loss.
Keywords
* GLP-1 agonist
* semaglutide
* weight loss
* hair loss
* drug safety
## INTRODUCTION
Glucagon-like peptide-1 (GLP-1) agonists are one of the most prescribed classes of drugs worldwide and are indicated for the treatment of diabetes or obesity. Approximately 1 in 8 people in the USA have used GLP-1 agonists1. Several studies have addressed the adverse event profiles of these drugs but have focussed mainly on the gastrointestinal adverse events2. Anecdotal data has alluded to hair loss as another adverse event associated with semaglutide. Data from the Food and Drug Administration (FDA) have reported more hair loss events with GLP-1 agonists compared to other antihyperglycemics3. However, to date, no epidemiologic study has examined this association in a real-life clinical setting especially in those taking semaglutide purely for weight loss.
## METHODS
Our data included a random sample of 16 million patients (2006-2020) from the IQVIA PharMetrics® Plus for Academics. It captures 93% of all outpatient prescriptions and physician diagnoses in the US through the *International Classification of Diseases, Ninth and Tenth Revisions (ICD-9 or 10)*. We included new users of semaglutide, the most prescribed GLP-1 agonist, and the active comparator bupropion-naltrexone, a weight loss agent unrelated and chemically distinct to semaglutide. Those with a diagnosis of diabetes or use of an antihyperglycemic before cohort entry were excluded. This cohort was previously described by Sodhi2. Cohort members were followed from the first date of a study drug prescription to the first diagnosis of hair loss defined by the first ICD-9 (704.0X) or ICD-10 (L63.0, L63.1, L63.9, L64.0, L 64.8, L64.9, L65.0, L65.1, L 65.8, L65.9) code for the condition or termination of follow up. A Cox regression model was used to compute hazard ratios (HRs) that adjusted for age, sex, geographic location, depression, anemia, hypothyroidism, polycystic ovary syndrome, and use of oral corticosteroids. All analyses were performed using SAS version 9.4. Ethics approval was obtained by the University of British Columbia’s clinical research ethics board with a waiver of informed consent.
## RESULTS
Our cohort included 1,926 semaglutide users and 1,348 users of bupropion-naltrexone (Table 1). Bupropion-naltrexone users were younger than semaglutide users (Table 1). Incidence rates for hair loss for semaglutide and bupropion-naltrexone users was 26.5/1,000 and 11.8/1,000 person-years respectively (Table 1). The crude hazard ratio for hair loss for all patients taking semaglutide, for men, and for women was 1.30 (95% confidence interval (CI): 0.74-2.28), 0.70 (95% CI: 0.04-11.43), and 1.94 (95% CI: 1.09-3.54) respectively (Table 2). The adjusted hazard ratio for hair loss for all patients using semaglutide, for men, and for women compared to bupropion-naltrexone were 1.52 (95% CI: 0.86-2.69), 0.86 (95% CI: 0.05-14.49), and 2.08 (95% CI: 1.17-3.72) respectively (Table 2).
View this table:
[Table 1.](http://medrxiv.org/content/early/2025/03/06/2025.02.23.25322568/T1)
Table 1. Characteristics of semaglutide, liraglutide, and bupropion-naltrexone users.
View this table:
[Table 2.](http://medrxiv.org/content/early/2025/03/06/2025.02.23.25322568/T2)
Table 2. Hazard ratios and 95% confidence intervals of hair loss among semaglutide users compared to bupropion-naltrexone users including an analysis stratified by sex.
## DISCUSSION
This study shows that semaglutide is associated with hair loss compared to users of bupropion-naltrexone. Although we found an increase in the overall HRs, the confidence intervals were imprecise leading to inconclusive results. However, when we stratified the results by sex, we note a greater than double increase in the HR in women.
Our results are in line with a clinical trial data for semaglutide (Wegovy®) that also showed an elevated risk of hair loss (3.3% in the Wegovy® group compared to 1.4% in the placebo, RR=2.38, 95% 1.41-4.0) compared to placebo users4. Although not fully elucidated, it is postulated that hair loss secondary to semaglutide might be due to the physiological stress that rapid weight loss can induce, causing telogen effluvium and leading to increased hair shedding5. This may be more prominent with semaglutide as it is known to decrease weight more rapidly than bupropion-naltrexone, thus inducing greater physiological stress on the body and thus potentially greater hair loss6. Furthermore, in the Wegovy® trial, those with greater than 20% body weight reduction reported alopecia more than those losing less than 20% of their body weight (5.3% versus 2.5%)4. This further lends credence that the mechanism for semaglutide induced hair loss may be due to the physiologic stress on the body that rapid weight loss induces, thus disrupting the hair cycle, leading to hair loss3,4. It is also possible that due to semaglutide’s appetite suppressive properties, patients have less food intake that can potentially cause nutrient deficiencies, and in particular, protein deficiencies which has been shown to be associated with hair loss3. Additionally, in conjunction with other potential adverse effects of semaglutide use such as nausea and gastroparesis2, total oral intake may decrease and loss of nutrients through vomitus can occur3.
Lastly, it has been hypothesized that semaglutide can lead to hormonal shifts that increase the risk of androgenic alopecia, whereby patients experience thinner hair and may potentially stop developing appreciable hair strands that can result in permeant hair loss, despite cessation of treatment3,7.
Limitations of our study include lack of data on semaglutide’s indication. Although we have excluded those with diabetes and those taking antihyperglycemics in the year prior to cohort entry, we cannot be certain that patients were taking semaglutide solely for weight loss.
Those considering using semaglutide strictly for weight loss might want to factor in hair loss as a possible limitation of these drugs, and in particular, women who may want to use semaglutide.
The risk benefit calculus to treatment initiation may be different for those with diabetes or morbid obesity and they may be more willing to accept hair loss as a potential risk of semaglutide treatment than those using semaglutide for recreational weight loss. Future studies are required to ascertain the association between GLP-1 agonists and hair loss.
## Data Availability
All data produced in the present study are available upon reasonable request to the authors.
## Author Contributions
Dr. Etminan had full access to all the data and takes responsibility for the integrity and accuracy of the data.
*Concept and design:* Etminan and Sodhi
*Acquisition, analysis, or interpretation of data:* All authors
*Drafting of the manuscript:* Etminan, Sodhi, Rezaeianzadeh, and Frey
*Critical revision of the manuscript for important intellectual content:* All authors
*Statistical analysis:* Kezouh
*Obtained funding:* Etminan
*Supervision:* Etminan
## Conflict of Interest Disclosures
Dr. Etminan has previously consulted on the Ozempic litigation.
## Funding/Support
This study was funded by internal research funds from the Department of Ophthalmology and Visual Sciences, University of British Columbia.
## Role of the Funder/Sponsor
The funding organization did not have any role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.
## Data Sharing Agreement
We will not be sharing the data, however we are open to answering any questions regarding collection, management, analysis, or interpretation of our data source.
## Footnotes
* 1. We changed "alopecia areata" to "hair loss" throughout the whole manuscript. 2. We added the specific ICD9 and 10 codes in the methods section used to identify hair loss diagnoses. 3. The results of the study changed when including different diagnosis codes. 4. We only included semaglutide as a study drug and excluded liraglutide. 5. We added more information in the discussion on the potential mechanism for semaglutide induced hair loss.
* Received February 23, 2025.
* Revision received March 5, 2025.
* Accepted March 6, 2025.
* © 2025, Posted by Cold Spring Harbor Laboratory
This pre-print is available under a Creative Commons License (Attribution 4.0 International), CC BY 4.0, as described at [http://creativecommons.org/licenses/by/4.0/](http://creativecommons.org/licenses/by/4.0/)
## REFERENCES
1. 1.Harris E. Poll: Roughly 12% of US Adults Have Used a GLP-1 Drug, Even If Unaffordable. JAMA. 2024;332(1):8.
2. 2.Sodhi M, Rezaeianzadeh R, Kezouh A, Etminan M. Risk of Gastrointestinal Adverse Events Associated With Glucagon-Like Peptide-1 Receptor Agonists for Weight Loss. JAMA. 2023;330(18):1795–1797.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1001/jama.2023.19574&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=37796527&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F03%2F06%2F2025.02.23.25322568.atom)
3. 3.Nakhla M, Nair A, Balani P, et al. Risk of Suicide, Hair Loss, and Aspiration with GLP1-Receptor Agonists and Other Diabetic Agents: A Real-World Pharmacovigilance Study [published online September 12, 2024]. Cardiovasc Drugs Ther. doi: 10.1007/s10557-024-07613-w.
[CrossRef](http://medrxiv.org/lookup/external-ref?access_num=10.1007/s10557-024-07613-w&link_type=DOI)
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=39264502&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F03%2F06%2F2025.02.23.25322568.atom)
4. 4. Novo Nordisk. Wegovy ® Product Monograph. [https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Wegovy-product-monograph.pdf](https://www.novonordisk.ca/content/dam/nncorp/ca/en/products/Wegovy-product-monograph.pdf). Accessed February 15, 2024.
5. 5.Desai DD, Sikora M, Nohria A, et al. GLP-1 agonists and hair loss: a call for further investigation. Int J Dermatol. 2024;63(9):1128–1130.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=38741261&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F03%2F06%2F2025.02.23.25322568.atom)
6. 6.Sherman MM, Ungureanu S, Rey JA. Naltrexone/Bupropion ER (Contrave): Newly Approved Treatment Option for Chronic Weight Management in Obese Adults. P T. 2016;41(3):164–72.
[PubMed](http://medrxiv.org/lookup/external-ref?access_num=26957883&link_type=MED&atom=%2Fmedrxiv%2Fearly%2F2025%2F03%2F06%2F2025.02.23.25322568.atom)
7. 7.Misuse of Ozempic for Rapid Weight Loss Can Cause Significant and Perhaps Permanent Hair Loss. Dermatology Times. [https://www.dermatologytimes.com/view/misuse-of-ozempic-for-rapid-weight-loss-can-cause-significant-and-perhaps-permanent-hair-loss](https://www.dermatologytimes.com/view/misuse-of-ozempic-for-rapid-weight-loss-can-cause-significant-and-perhaps-permanent-hair-loss). Accessed March 3, 2025.